



FILE COPY

September 10, 2002

Nicholas M. Fleischer, R.Ph., Ph.D.
Director of Biopharmaceutics
The Weinberg Group Inc.
1220 Nineteenth Street, N.W., Suite 300
Washington, DC 20036-2400

Dear Dr. Fleischer:

Your petition requesting the Food and Drug Administration to declare that Amoxicillin and Clavulanate Potassium Tablets for Oral Suspension 200 mg/28.5 mg, 400 mg/57 mg and 600 mg/42.9 mg are suitable for submission as an abbreviated new drug application was received by this office on 09/10/02. It was assigned docket number 02P-0406/CP 1 and it was filed on 09/10/02. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Lyle D. Jaffe
Dockets Management Branch

02 P 0406

ACK 1